Regulatory measures used to cap prescription costs in the U.S. and Europe won’t work here, a Competition Bureau conference has been told. Canada’s smaller population can only spell less competition between brand name and generic companies, cautioned an economist: “Many companies don’t even come to Canada.”
This content is for Blacklock’s Reporter members only. Please login to view this content. (Register here.)
